OR WAIT null SECS
December 28, 2023
Tome Bioscience is facilitating the transition in biology from the editing phase to the cut-and-paste phase.
December 27, 2023
The midterm report of the European Medicines Agencies Network Strategy finds that the network has strengthened and is on track to achieve its objectives.
Andelyn Biosciences has been selected by Ultragenyx to manufacture UX111, that company’s gene therapy for treating Sanfilippo Syndrome.
December 26, 2023
WHO provides a look at the world’s health as the agency turns 75.
December 21, 2023
The final guidance document provides recommendations for designing a new registry or using an existing registry to support decisions regarding safety and effectiveness of a drug.
The agencies published a joint guidance document regarding quality development for breakthrough therapies and PRIME programs.
December 20, 2023
Under a collaboration, Daiichi Sankyo and Depixus will use Depixus’ MAGNA technology to accelerate drug discovery efforts of RNA-targeted therapeutics.
Following the divestiture of its Elusys subsidiary and other non-core assets, NightHawk Biosciences will transform into a pure-play large-molecule CDMO.
December 19, 2023
Bristol Myers Squibb and SystImmune plan to co-develop and co-commercialize lead ADC candidate for cancer treatment in US.
December 18, 2023
The Multi-annual AI Workplan creates a strategy to maximize the benefits and manage the risks of artificial intelligence.